Canadian Supreme Court decision on GlaxoSmithKline’s transfer pricing

International Tax Review is part of Legal Benchmarking Limited, 1-2 Paris Garden, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement


Canadian Supreme Court decision on GlaxoSmithKline’s transfer pricing

The Canadian Supreme Court (SC) has today delivered its first transfer pricing decision, in a case involving GlaxoSmithKline (GSK).

gsk150.jpg

The SC dismissed the appeal by the Canada Revenue Agency (CRA) of a ruling by the Federal Court concerning the deductibility of the price paid by GSK Canada to a Swiss related-entity. The CRA said the payment was not reasonable in the circumstances and a reasonable payment would have been that paid by generic companies.

GSK Canada said the consideration of reasonableness should take into account the licence agreement between the GSK group of companies and GSK Canada, which agreed a 6% royalty should be paid to the GSK group on sales of drugs covered by the agreement.

The trial judge ignored this and ruled the price GSK Canada should have paid was the highest of that paid by generic companies. This was overruled by the Federal Court in July 2010.

It has taken the SC judges 10 months to come to a decision after the hearing on January 13.

The SC held that the determination of an arm’s-length price must be informed by relevant surrounding economic circumstances, including other transactions that may be related to the purchasing transaction.

The case will now return to the Tax Court of Canada for redetermination because the SC also dismissed GSK’s cross-appeal, which asked it to overturn the decision of the Federal Court of Appeal to remit the matter to the Tax Court.

How GSK’s Canada SC hearing unfolded

Canadian Supreme Court confirms GSK date

GlaxoSmithKline files its arguments to Supreme Court of Canada

Supreme Court of Canada accepts Glaxo case

Glaxo prevails in the Canadian Federal Court of Appeal

Glaxo Canada: the key issues

Glaxo Canada loses transfer pricing case

more across site & shared bottom lb ros

More from across our site

KPMG's UK head of tax policy discusses what the Budget means for businesses, whether pillar two has survived its US carve-out, and why taxing wealth could become the next global debate
The appointments of Thomas Gaughan and Daniel Martinez further signal that the private client advisory market is booming
The rebrand, which MHA said would make its connection to the Baker Tilly network ‘clear’, will take effect in February
The stars of Weil’s heavyweight tax practices are up for grabs, but recruiting firms will need to be patient to secure a package deal
Meta has overtaken Amazon as the ‘Silicon Six’ business with the worst tax conduct, according to the Fair Tax Foundation
Awards
It was also a memorable night for Baker McKenzie and its associated firms, after picking up 19 awards, including the coveted Asia-Pacific Tax Law Firm of the Year
Stocche Forbes Advogados, Utumi Advogados and Lobo de Rizzo Advogados have reached Tier 2 as competition intensifies in the region’s largest tax market
Ben Webster’s arrival represents a significant expansion of Withers’ London tax litigation practice, as the private client firm eyes further international growth
The combination swiftly builds on RSM’s addition of a new Lithuanian firm to its international network, signalling a European build-out
Tax teams must look beyond pillar two’s headline rules as R&D incentives and the US side-by-side deal create new strategic choices for multinationals, says Marta Pankiv of Tricentis
Gift this article